Nature Reviews Clinical Oncology

Vol. 22, Issue 12 Issue 12 2025
13
Articles

Articles in this Issue

Perioperative therapy effective in high-risk HCC

Peter Sidaway Dec 01, 2025 pp. 899-899 10.1038/s41571-025-01091-1

Belzutifan as a new option in pheochromocytomas and paragangliomas

Diana Romero Dec 01, 2025 pp. 899-899 10.1038/s41571-025-01092-0

Sacituzumab tirumotecan improves OS in EGFR TKI-resistant NSCLC

David Killock Dec 01, 2025 pp. 899-899 10.1038/s41571-025-01090-2

HER2-directed therapy improves urothelial cancer outcomes

David Killock Dec 01, 2025 pp. 898-898 10.1038/s41571-025-01089-9

Combination neoadjuvant chemotherapy improves outcomes

Peter Sidaway Dec 01, 2025 pp. 898-898 10.1038/s41571-025-01086-y

Ivonescimab delays disease progression

Peter Sidaway Dec 01, 2025 pp. 898-898 10.1038/s41571-025-01088-w

Clinical relevance of extracellular vesicles in cancer — therapeutic and diagnostic potential

David W. Greening, Rong Xu, Alin Rai et al. Dec 01, 2025 pp. 924-952 10.1038/s41571-025-01074-2

Author Correction: Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care

Alireza Mansouri, Ahmad Ozair, Debarati Bhanja et al. Dec 01, 2025 pp. 996-996 10.1038/s41571-025-01083-1

The tumour microenvironment in pancreatic cancer — new clinical challenges, but more opportunities

Heng-Chung Kung, Kevin W. Zheng, Jacquelyn W. Zimmerman et al. Dec 01, 2025 pp. 969-995 10.1038/s41571-025-01077-z

Optimizing CAR T cell therapy for solid tumours: a clinical perspective

Jiarui Li, Chang Liu, Panpan Zhang et al. Dec 01, 2025 pp. 953-968 10.1038/s41571-025-01075-1

Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities

Karl Petri, Elvira D’Ippolito, Annette Künkele et al. Dec 01, 2025 pp. 902-923 10.1038/s41571-025-01072-4

Non-financial conflicts of interest

Saroj Niraula, Ian F. Tannock Dec 01, 2025 pp. 895-897 10.1038/s41571-025-01073-3

Exercise as a new therapeutic modality in oncology: CHALLENGE trial refines survivorship care

Justin Y. Jeon Dec 01, 2025 pp. 900-901 10.1038/s41571-025-01071-5

All Issues

Issue 7 - Issue 7 11 Issue 6 - Issue 6 10 Issue 5 - Issue 5 10 Issue 4 - Issue 4 10 Issue 3 - Issue 3 10 Issue 2 - Issue 2 9 Issue 1 - Issue 1 12
Issue 9 - Issue 9 11 Issue 8 - Issue 8 14 Issue 7 - Issue 7 10 Issue 6 - Issue 6 9 Issue 5 - Issue 5 11 Issue 4 - Issue 4 10 Issue 3 - Issue 3 12 Issue 2 - Issue 2 8 Issue 12 - Issue 12 13 Issue 11 - Issue 11 9 Issue 10 - Issue 10 8 Issue 1 - Issue 1 12

Journal Info

Publisher Springer Science and Business Media LLC
ISSN 1759-4774
E-ISSN 1759-4782
Subject Medicine
Language English
View Full Journal Page